PetVivo (NASDAQ:PETV) Trading 1.1% Higher

PetVivo Holdings, Inc. (NASDAQ:PETV) shares traded up 1.1% on Wednesday . The stock traded as high as $0.46 and last traded at $0.46. 23,653 shares traded hands during trading, a decline of 44% from the average session volume of 42,518 shares. The stock had previously closed at $0.45.

PetVivo Stock Performance

The company has a debt-to-equity ratio of 0.02, a current ratio of 0.90 and a quick ratio of 0.62. The company’s fifty day simple moving average is $0.67 and its two-hundred day simple moving average is $0.93. The stock has a market cap of $10.33 million, a price-to-earnings ratio of -0.60 and a beta of 2.24.

Insiders Place Their Bets

In other news, CEO John Lai bought 150,000 shares of PetVivo stock in a transaction dated Monday, April 15th. The stock was purchased at an average price of $0.60 per share, for a total transaction of $90,000.00. Following the purchase, the chief executive officer now directly owns 1,288,592 shares in the company, valued at approximately $773,155.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 20.10% of the company’s stock.

Institutional Trading of PetVivo

An institutional investor recently bought a new position in PetVivo stock. Warberg Asset Management LLC purchased a new stake in shares of PetVivo Holdings, Inc. (NASDAQ:PETV) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 27,693 shares of the company’s stock, valued at approximately $29,000. Warberg Asset Management LLC owned 0.19% of PetVivo as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 24.55% of the company’s stock.

PetVivo Company Profile

PetVivo Holdings, Inc, a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses.